{
    "ticker": "ORGS",
    "name": "Organogenesis Holdings Inc.",
    "description": "Organogenesis Holdings Inc. is a leading regenerative medicine company focused on developing and commercializing innovative products in the fields of wound care and surgical biologics. Founded in 1985 and headquartered in Canton, Massachusetts, Organogenesis is dedicated to providing advanced solutions that promote healing and improve patient outcomes. The company\u2019s product portfolio includes a range of allograft and cellular therapy products, such as Apligraf and Dermagraft, which are designed to treat complex wounds and accelerate tissue regeneration. Organogenesis leverages cutting-edge science and technology to create therapies that address significant unmet medical needs, particularly in the management of chronic wounds and surgical applications. With a strong commitment to research and development, the company collaborates with leading medical professionals and institutions to advance the field of regenerative medicine. Organogenesis is driven by its mission to help patients heal faster and more effectively, ultimately enhancing their quality of life. As it continues to expand its product offerings and reach more patients, Organogenesis remains at the forefront of innovation in the healthcare industry.",
    "industry": [
        "Biotechnology",
        "Healthcare"
    ],
    "headquarters": "Canton, Massachusetts, USA",
    "founded": "1985",
    "website": "https://www.organogenesis.com",
    "ceo": "Gary S. Gillheeney",
    "social_media": {
        "twitter": "https://twitter.com/Organogenesis",
        "linkedin": "https://www.linkedin.com/company/organogenesis/"
    },
    "investor_relations": "https://investors.organogenesis.com",
    "key_executives": [
        {
            "name": "Gary S. Gillheeney",
            "position": "CEO"
        },
        {
            "name": "Michael D. Dyer",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Wound Care Products",
            "products": [
                "Apligraf",
                "Dermagraft"
            ]
        },
        {
            "category": "Surgical Biologics",
            "products": [
                "FlexiGraft",
                "OsteoSet"
            ]
        }
    ],
    "seo": {
        "meta_title": "Organogenesis Holdings Inc. | Regenerative Medicine Solutions",
        "meta_description": "Explore Organogenesis Holdings Inc., a leader in regenerative medicine focused on innovative wound care and surgical biologics. Discover our advanced healing solutions.",
        "keywords": [
            "Organogenesis",
            "Regenerative Medicine",
            "Wound Care",
            "Surgical Biologics",
            "Apligraf",
            "Dermagraft"
        ]
    },
    "faq": [
        {
            "question": "What does Organogenesis specialize in?",
            "answer": "Organogenesis specializes in regenerative medicine, focusing on advanced wound care and surgical biologics."
        },
        {
            "question": "Who is the CEO of Organogenesis?",
            "answer": "Gary S. Gillheeney is the CEO of Organogenesis Holdings Inc."
        },
        {
            "question": "Where is Organogenesis headquartered?",
            "answer": "Organogenesis is headquartered in Canton, Massachusetts, USA."
        },
        {
            "question": "What are some of Organogenesis's main products?",
            "answer": "Key products include Apligraf and Dermagraft for wound care."
        },
        {
            "question": "When was Organogenesis founded?",
            "answer": "Organogenesis was founded in 1985."
        }
    ],
    "competitors": [
        "TEVA",
        "AXGN",
        "PSTG",
        "ISRG"
    ],
    "related_stocks": [
        "JNJ",
        "ABBV",
        "MRK",
        "GILD"
    ]
}